Atalanta Sosnoff Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.01M | Sell |
7,988
-270,349
| -97% | -$58.2M | 0.04% | 61 |
|
|
2026
Q1 | $60.5M | Sell |
278,337
-218,205
| -44% | -$48.4M | 1.3% | 28 |
|
|
2025
Q4 | $113M | Sell |
496,542
-5,129
| -1% | -$1.17M | 2.21% | 15 |
|
|
2025
Q3 | $116M | Sell |
501,671
-10,107
| -2% | -$2.06M | 2.23% | 14 |
|
|
2025
Q2 | $95M | Buy |
511,778
+97,017
| +23% | +$18M | 1.93% | 17 |
|
|
2025
Q1 | $86.9M | Buy |
414,761
+10,363
| +3% | +$2.01M | 2.08% | 17 |
|
|
2024
Q4 | $71.9M | Sell |
404,398
-23,377
| -5% | -$4.3M | 1.56% | 22 |
|
|
2024
Q3 | $84.5M | Buy |
427,775
+105,220
| +33% | +$19.6M | 1.81% | 16 |
|
|
2024
Q2 | $55.3M | Sell |
322,555
-143,982
| -31% | -$23.9M | 1.25% | 27 |
|
|
2024
Q1 | $85M | Sell |
466,537
-1,959
| -0.4% | -$338K | 1.96% | 10 |
|
|
2023
Q4 | $72.6M | Buy |
468,496
+176,698
| +61% | +$25.8M | 1.87% | 15 |
|
|
2023
Q3 | $43.5M | Buy |
291,798
+290,189
| +18,035% | +$42.6M | 1.29% | 28 |
|
|
2023
Q2 | $217K | Hold |
1,609
| – | – | 0.01% | 99 |
|
|
2023
Q1 | $256K | Sell |
1,609
-69
| -4% | -$10.5K | 0.01% | 100 |
|
|
2022
Q4 | $271K | Sell |
1,678
-308
| -16% | -$47.2K | 0.01% | 95 |
|
|
2022
Q3 | $267K | Buy |
1,986
+523
| +36% | +$75K | 0.01% | 79 |
|
|
2022
Q2 | $224K | Sell |
1,463
-40
| -3% | -$6.11K | 0.01% | 95 |
|
|
2022
Q1 | $244K | Buy |
+1,503
| New | +$218K | 0.01% | 104 |
|
|
2021
Q1 | – | Sell |
-2,201
| Closed | -$236K | – | 99 |
|
|
2020
Q4 | $236K | Buy |
+2,201
| New | +$212K | 0.01% | 91 |
|
|
2018
Q3 | – | Sell |
-3,670
| Closed | -$340K | – | 79 |
|
|
2018
Q2 | $340K | Hold |
3,670
| – | – | 0.01% | 70 |
|
|
2018
Q1 | $347K | Sell |
3,670
-50
| -1% | -$5.49K | 0.01% | 75 |
|
|
2017
Q4 | $360K | Buy |
+3,720
| New | +$351K | 0.01% | 74 |
|
|
2017
Q3 | – | Sell |
-4,650
| Closed | -$337K | – | 86 |
|
|
2017
Q2 | $337K | Sell |
4,650
-435,590
| -99% | -$29.3M | 0.01% | 82 |
|
|
2017
Q1 | $28.7M | Sell |
440,240
-372,510
| -46% | -$23.4M | 1.01% | 45 |
|
|
2016
Q4 | $50.9M | Buy |
812,750
+124,355
| +18% | +$7.59M | 1.81% | 19 |
|
|
2016
Q3 | $43.4M | Buy |
688,395
+353,072
| +105% | +$22.9M | 1.5% | 29 |
|
|
2016
Q2 | $20.8M | Buy |
+335,323
| New | +$20.4M | 0.69% | 54 |
|
|
2015
Q2 | – | Sell |
-19,353
| Closed | -$1.13M | – | 100 |
|
|
2015
Q1 | $1.13M | Hold |
19,353
| – | – | 0.03% | 84 |
|
|
2014
Q4 | $1.27M | Sell |
19,353
-32,880
| -63% | -$2.07M | 0.03% | 79 |
|
|
2014
Q3 | $3.02M | Buy |
52,233
+6,810
| +15% | +$378K | 0.07% | 57 |
|
|
2014
Q2 | $2.56M | Buy |
45,423
+3,200
| +8% | +$168K | 0.06% | 60 |
|
|
2014
Q1 | $2.17M | Sell |
42,223
-3,700
| -8% | -$187K | 0.05% | 58 |
|
|
2013
Q4 | $2.42M | Buy |
45,923
+300
| +0.7% | +$14.7K | 0.05% | 57 |
|
|
2013
Q3 | $2.04M | Sell |
45,623
-150
| -0.3% | -$6.65K | 0.05% | 53 |
|
|
2013
Q2 | $1.89M | Buy |
+45,773
| New | +$2M | 0.05% | 54 |
|
Other funds holding ABBV
Atalanta Sosnoff Capital's ABBV Position: Q2 2026 in Review
Atalanta Sosnoff Capital reduced its AbbVie (ABBV) stake by 97% in Q2 2026, selling an estimated $58.2M and leaving 7,988 shares worth $2.01M. The position accounts for 0.04% of the portfolio, ranked #61.
Atalanta Sosnoff Capital first reported a position in ABBV in Q2 2013 and has held it in 35 quarters since. The position peaked at $116M in Q3 2025. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Atalanta Sosnoff Capital held 7,988 shares of AbbVie worth $2.01M as of Q2 2026.
- Atalanta Sosnoff Capital sold 270,349 AbbVie shares in Q2 2026, an estimated $58.2M.
- AbbVie made up 0.04% of Atalanta Sosnoff Capital's portfolio in Q2 2026, its #61 holding.
- Atalanta Sosnoff Capital first reported a position in AbbVie in Q2 2013 and has held it in 35 quarters since.
- Atalanta Sosnoff Capital's AbbVie position peaked at $116M in Q3 2025.
- 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Atalanta Sosnoff Capital's 13F filing for Q2 2026, filed 12 Aug 2026.